TP-3654
sumitomo dainippon
['sumitomo']
sumitomo pharma oncology, inc. presents updated preliminary data from phase 1/2 clinical study evaluating investigational agent tp-3654 in patients with myelofibrosis at european hematology association 2023 hybrid congress #prnewswire #prnewswire 
Stock Market News and Press Releases. #StockMarket & #Crypto